Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Multidrug resistance (MDR) is a significant challenge in chemotherapy, often mediated by MDR1 gene overexpression.
• P-glycoprotein (P-gp), encoded by MDR1, actively effluxes drugs, reducing treatment efficacy.
• Existing P-gp inhibitors exhibit high toxicity, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To investigate the potential of small interfering RNAs (siRNAs) for selective MDR1 gene modulation.
• To assess the efficacy of siRNAs in down-regulating P-gp expression and reversing the MDR phenotype.
• To evaluate the impact of siRNA treatment on chemosensitivity in drug-resistant cancer cells.

Main Methods:

• Utilized two specific siRNAs at low concentrations (5-20 nM) to target MDR1 in doxorubicin-selected MCF7-R human cell lines.
• Quantified MDR1 mRNA and P-gp protein expression levels.
• Assessed P-gp cell surface expression and drug efflux inhibition.
• Measured the enhancement of chemosensitivity.

Main Results:

• Efficient down-regulation of MDR1 at the protein level was achieved, with approximately 20% of P-gp expression remaining.
• siRNA treatment inhibited cell surface P-gp expression, leading to a significant reversal of the drug efflux phenotype (up to 40%).
• Chemosensitivity was enhanced by approximately 35% in siRNA-treated cells.
• MDR1 mRNA down-regulation increased with siRNA concentration, reaching 60% at 20 nM.

Conclusions:

• Low-concentration siRNAs are effective tools for selective MDR1 gene modulation.
• siRNA-mediated P-gp inhibition reverses drug resistance and enhances chemosensitivity.
• Further investigation into combination siRNA therapy may offer improved therapeutic outcomes.